Lymphoma and Non-Acute Leukemia DRG 824 Reimbursement

DRG 824 includes hospital stays for lymphoma and non-acute leukemia involving other procedures with at least one Complication or Comorbidity, reflecting moderate clinical complexity. Correct grouping affects inpatient reimbursement under Medicare by aligning payment with procedure intensity and patient acuity.

DRG 824 Overview

DRG 824 covers hospital admissions for patients with lymphoma and non-acute leukemia who undergo other significant diagnostic or therapeutic procedures and have at least one Complication or Comorbidity. This Diagnosis-Related Group captures cases with moderate clinical complexity where the procedures and presence of Complication or Comorbidity affect resource use. It matters for Medicare inpatient payment because the grouping determines relative reimbursement for hospitals under the Inpatient Prospective Payment System, reflecting procedure intensity and patient acuity. Accurate coding of principal diagnosis, secondary diagnoses, and procedures is central to correct assignment to this Diagnosis-Related Group and corresponding payment.

Studies of inpatient-adjunct procedural strategies and perioperative management for lymphoma and chronic (non-acute) leukemia patients undergoing diagnostic or therapeutic procedures: these trials assess protocols for procedures commonly coded as “other procedures” (such as lymph node excisional biopsy, tunneled central line placement, bone marrow or targeted biopsy, or palliative surgical/embolization procedures) to reduce peri-procedural complications and length of stay. The patient population includes hospitalized adults with lymphoma or indolent leukemias who have comorbidities or treatment-related cytopenias that increase procedural risk; outcomes measured include bleeding, infection, transfusion needs, and 30-day readmission. This research is directly relevant to hospitals and payers because reducing procedure-related complications and short inpatient stays can lower costs, improve DRG case-mix management, and inform appropriate bundling of services under the DRG.
Comparative effectiveness trials of inpatient systemic or supportive therapies aimed at management of disease-related complications in non-acute leukemia and lymphoma: these studies compare approaches such as dose-modified chemotherapy, targeted outpatient-to-inpatient transition strategies, or intensified supportive care regimens (growth factors, antimicrobial prophylaxis strategies, transfusion thresholds) for patients admitted with symptomatic disease or treatment complications. The enrolled group is hospitalized patients with lymphoma or chronic leukemia experiencing complications like symptomatic cytopenias, febrile neutropenia risk, or tumor-related organ compromise; primary questions evaluate clinical recovery time, avoidance of intensive care, and short-term mortality. Results guide clinicians and payers on which inpatient therapeutic pathways produce better short-term outcomes and resource utilization for this DRG, informing care protocols and reimbursement considerations.
Post-discharge outcomes and care-coordination studies focusing on readmission reduction and transition-of-care models for lymphoma and non-acute leukemia patients with complications: these observational and interventional studies examine discharge planning, early outpatient follow-up, home-based nursing or transfusion services, and telehealth monitoring to prevent readmission among high-risk patients. The population includes patients under DRG 824 discharged after an admission involving procedures or treatment with concurrent complications or comorbidities (CC), with endpoints like 30- and 90-day readmission rates, emergency visits, and pharmacy utilization. Findings are important for providers and payers because effective post-discharge models can decrease costly readmissions, improve patient outcomes, and influence value-based payment strategies tied to this DRG.

Studies of inpatient-adjunct procedural strategies and perioperative management for lymphoma and chronic (non-acute) leukemia patients undergoing diagnostic or therapeutic procedures: these trials assess protocols for procedures commonly coded as “other procedures” (such as lymph node excisional biopsy, tunneled central line placement, bone marrow or targeted biopsy, or palliative surgical/embolization procedures) to reduce peri-procedural complications and length of stay. The patient population includes hospitalized adults with lymphoma or indolent leukemias who have comorbidities or treatment-related cytopenias that increase procedural risk; outcomes measured include bleeding, infection, transfusion needs, and 30-day readmission. This research is directly relevant to hospitals and payers because reducing procedure-related complications and short inpatient stays can lower costs, improve DRG case-mix management, and inform appropriate bundling of services under the DRG.
Comparative effectiveness trials of inpatient systemic or supportive therapies aimed at management of disease-related complications in non-acute leukemia and lymphoma: these studies compare approaches such as dose-modified chemotherapy, targeted outpatient-to-inpatient transition strategies, or intensified supportive care regimens (growth factors, antimicrobial prophylaxis strategies, transfusion thresholds) for patients admitted with symptomatic disease or treatment complications. The enrolled group is hospitalized patients with lymphoma or chronic leukemia experiencing complications like symptomatic cytopenias, febrile neutropenia risk, or tumor-related organ compromise; primary questions evaluate clinical recovery time, avoidance of intensive care, and short-term mortality. Results guide clinicians and payers on which inpatient therapeutic pathways produce better short-term outcomes and resource utilization for this DRG, informing care protocols and reimbursement considerations.
Post-discharge outcomes and care-coordination studies focusing on readmission reduction and transition-of-care models for lymphoma and non-acute leukemia patients with complications: these observational and interventional studies examine discharge planning, early outpatient follow-up, home-based nursing or transfusion services, and telehealth monitoring to prevent readmission among high-risk patients. The population includes patients under DRG 824 discharged after an admission involving procedures or treatment with concurrent complications or comorbidities (CC), with endpoints like 30- and 90-day readmission rates, emergency visits, and pharmacy utilization. Findings are important for providers and payers because effective post-discharge models can decrease costly readmissions, improve patient outcomes, and influence value-based payment strategies tied to this DRG.

OpenPayer

Summary & Overview

Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

DRG 824 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes